[1] 中华人民共和国卫生部.临床输血技术规范[EB/OL].(2000-06-02). http://www.nhc.gov.cn/yzygj/s3589/200804/adac19e63a4f49acafab8e0885bf07e1.shtml.
[2] 彭黎明,邓承祺,主编.现代血栓与止血的实验室检测及其应用[M].北京:人民卫生出版社,2004:617-620.
[3] GREENBERG S M,ZIAI W C,CORDONNIER C,et al.2022 guideline for the management of patients with spontaneous intracerebral hemorrhage:a guideline from the American heart association/american stroke association[J].Stroke,2022,53(7):e282-e361.
[4] HOLBROOK A,SCHULMAN S,WITT D M,et al.Evidence-based management of anticoagulant therapy:antithrombotic therapy and prevention of thrombosis,9th Ed:American college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e152S-e184S.
[5] 李莹,主编.临床检验基础[M].长春:吉林大学出版社[M].2016:76-77.
[6] MOORE G W.Testing for lupus anticoagulants[J].Semin Thromb Hemost,2022,48(6):643-660.
[7] BARBHAIYA M,ZUILY S,NADEN R,et al.2023 ACR/EULAR antiphospholipid syndrome classification criteria[J].Ann Rheum Dis,2023,82(10):1258-1270.
[8] SAMMARITANO L R.Antiphospholipid syndrome[J].Best Pract Res Clin Rheumatol,2020,34(1):101463.
[9] WEYAND A C,FLOOD V H.Von willebrand disease:curr-ent status of diagnosis and management[J].Hematol Oncol Clin North Am,2021,35(6):1085-1101.
[10] JAMES P D,CONNELL N T,AMEER B,et al.ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von willebrand disease[J].Blood Adv,2021,5(1):280-300.
[11] 中华医学会检验医学分会,国家卫生健康委临床检验中心,中国血友病协作组.血管性血友病实验诊断中国专家共识[J].中华检验医学杂志,2022,45(10):1034-1038.
[12] CONNELL N T,FLOOD V H,BRIGNARDELLO-PETERSEN R,et al.ASH ISTH NHF WFH 2021 guidelines on the management of von willebrand disease[J].Blood Adv,2021,5(1):301-325.
[13] 中华医学会血液学分会血栓与止血学组,中国血友病协作组.凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版)[J].中华血液学杂志,2018,39(10):793-799.
[14] VETRI D,LUMERA G,TARASCIO S,et al.A case of acquired factor V deficiency in patient with bleeding[J].TH Open,2020,4(2):e77-e79.
[15] 中华医学会血液学分会血栓与止血学组,中国血友病协作组.获得性血友病A诊断与治疗中国指南(2021年版)[J].中华血液学杂志,2021,42(10):793-799.
[16] RENNÉ T,SCHMAIER A H,NICKEL K F,et al.In vivo roles of factor XII[J].Blood,2012,120(22):4296-4303.
[17] 王晓梅. 凝血因子Ⅻ缺乏与出血症状的相关性分析[J].基层医学论坛,2022,26(34):71-73.
[18] L APOSTEL H J C,BIE B D,KATS S,et al.An unanticipated prolonged baseline ACT during cardiac surgery due to factor XII deficiency[J].Ann Card Anaesth,2022,25(2):229-232.
[19] 中华医学会血液学分会血栓与止血学组.血栓性血小板减少性紫癜诊断与治疗中国指南(2022年版)[J].中华血液学杂志,2022,43(1):7-12.
[20] SUKUMAR S,LÄMMLE B,CATALAND S R.Thrombotic thrombocytopenic Purpura:pathophysiology,diagnosis, and management[J].J Clin Med,2021,10(3):536.
[21] 阮长耿,余自强.2012版血栓性血小板减少性紫癜诊断与治疗中国专家共识解读[J].临床血液学杂志,2013,26(3):145-146.
[22] BIANCHINI E P.Antithrombin deficiency:no sugar,no diagnosis![J].Blood,2022,140(2):83-85.
[23] RODGERS G M,MAHAJERIN A.Antithrombin therapy:current state and future outlook[J].Clin Appl Thromb Hemost,2023,29:10760296231205279.
[24] ALLINGSTRUP M,WETTERSLEV J,RAVN F B,et al.Antithrombin III for critically ill patients:a systematic review with meta-analysis and trial sequential analysis[J].Intensive Care Med,2016,42(4):505-520.
[25] MACKMAN N,BERGMEIER W,STOUFFER G A,et al.Therapeutic strategies for thrombosis:new targets and approaches[J].Nat Rev Drug Discov,2020,19(5):333-352.
[26] EHRHARDT J D Jr,BONEVA D,MCKENNEY M,et al.Antithrombin deficiency in trauma and surgical critical care[J].J Surg Res,2020,256:536-542.
[27] 宋娟娟,刘柳,周虎.抗凝血酶的作用机制及其临床应用的研究进展[J].血栓与止血学,2023,29(1):47-51.
[28] 国家卫生健康委员会.围手术期患者血液管理指南[S].2022.
[29] NAIR P M,RENDO M J,REDDOCH-CARDENAS K M,et al. Recent advances in use of fresh frozen plasma, cryoprecipitate,immunoglobulins,and clotting factors for transfusion support in patients with hematologic disease[J].Semin Hematol,2020,57(2):73-82.
[30] GRIFOLS.THROMBATE III delivers 50x more antithrombin (AT) than the same amount of fresh frozen plasma (FFP)[EB/OL].[2024-02-20].https://www.thrombate.com/en/thrombate-iii-vs-frozen-plasma.
[31] BEATTIE G W,JEFFREY R R.Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery?[J].Interact Cardiovasc Thorac Surg,2014,18(1):117-120.
[32] SHI D Y,WANG S J.Advances of coagulation factor XIII[J].Chin Med J (Engl),2017,130(2):219-223.
[33] WOLBERG A S,SANG Y Q.Fibrinogen and factor XIII in venous thrombosis and Thrombus stability[J].Arterioscler Thromb Vasc Biol,2022,42(8):931-941.
[34] NOITZ M,BROOKS R,SZASZ J,et al.Acquired factor XIII deficiency is common during ECMO therapy and associated with major bleeding events and transfusion requirements[J].J Clin Med,2023,12(12):4115.
[35] BECKMAN J D,KASTHURI R S,WOLBERG A S,et al.Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors[J].Haemophilia,2018,24(6):e417-e420.
[36] 中华医学会血液学分会血栓与止血学组,中国血友病协作组.罕见遗传性出血性疾病诊断与治疗中国专家共识(2021年版)[J].中华血液学杂志,2021,42(2):89-96.
[37] 国家卫生健康委员会.全血和成分血使用[S].2018.
[38] 国家卫生健康委员会.内科输血[S].2018.
[39] PANDEY S,VYAS G N.Adverse effects of plasma transfusion[J]. Transfusion,2012,52(Suppl 1):65S-79S. |
